Tempus AI, Inc. $TEM Shares Sold by H&H International Investment LLC

H&H International Investment LLC lowered its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 81.8% during the first quarter, Holdings Channel reports. The fund owned 20,000 shares of the company’s stock after selling 90,000 shares during the quarter. Tempus AI makes up 0.0% of H&H International Investment LLC’s holdings, making the stock its 18th largest holding. H&H International Investment LLC’s holdings in Tempus AI were worth $904,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TEM. Aberdeen Group plc lifted its holdings in Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after acquiring an additional 102,878 shares during the period. Pictet Asset Management Holding SA increased its holdings in shares of Tempus AI by 291.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares in the last quarter. Bogart Wealth LLC lifted its stake in shares of Tempus AI by 365,087.5% in the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after purchasing an additional 58,414 shares during the period. Eagle Health Investments LP purchased a new stake in Tempus AI during the first quarter worth $11,588,000. Finally, Alethea Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at $1,863,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEM. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Wolfe Research started coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Monday, July 20th. Finally, Freedom Capital upgraded Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Trading Down 3.1%

Shares of Tempus AI stock opened at $41.55 on Thursday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The firm has a market capitalization of $7.46 billion, a PE ratio of -24.16 and a beta of 3.46. The firm’s 50-day moving average price is $51.49 and its 200 day moving average price is $52.92.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.24) earnings per share. On average, sell-side analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. The trade was a 9.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan M. Bartolucci sold 4,116 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the sale, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at $3,262,986.87. The trade was a 5.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 449,793 shares of company stock worth $23,248,231 in the last quarter. 24.26% of the stock is owned by insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.